Xilio Therapeutics Inc —— 资产负债表 (NASDAQ:XLO) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 218.06 M139.16 M60.93 M71.08 M154.69 M 负债总额 32.63 M33.52 M24.1 M53.48 M119.41 M 权益总额 185.43 M105.65 M36.83 M17.6 M35.27 M 负债及股东权益总额 218.06 M139.16 M60.93 M71.08 M154.69 M 总债务 9.71 M9.91 M12.5 M—— 净债务 -188.34 M-110.47 M-32.2 M——

新闻

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Xilio Therapeutics实施1股并14股的反向拆股

Xilio Therapeutics implements 1-for-14 reverse stock split

西利奥治疗公司从权证行权中获得3580万美元

Xilio Therapeutics secures $35.8 million from warrant exercises

Xilio Therapeutics报告从B系列权证行权中获得3580万美元收益

Xilio Development Q3 每股收益逊于预期, 营收超出预期

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript